Cognetivity Neurosciences (STU:1UB) EBIT: €-2.81 Mil (TTM As of Oct. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Cognetivity Neurosciences EBIT?

Cognetivity Neurosciences STU:1UB EBIT is €-2.81 Mil as of Oct. 2023.

Cognetivity Neurosciences's earnings before interest and taxes (EBIT) for the three months ended in Oct. 2023 was €-0.49 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Oct. 2023 was €-2.81 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Cognetivity Neurosciences's annualized ROC % for the quarter that ended in Oct. 2023 was -37.38%. Cognetivity Neurosciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Oct. 2023 was -5,741.18%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Cognetivity Neurosciences's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Oct. 2023 was -337.33%.

Cognetivity Neurosciences  (STU:1UB) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Cognetivity Neurosciences's annualized ROC % for the quarter that ended in Oct. 2023 is calculated as:

ROC % (Q: Oct. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jul. 2023 ) + Invested Capital (Q: Oct. 2023 ))/ count )
=-2.468 * ( 1 - 0% )/( (6.164 + 7.041)/ 2 )
=-2.468/6.6025
=-37.38 %

where

Invested Capital(Q: Jul. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=0.376 - 3.45 - ( 0.021 - max(0, 9.497 - 0.259+0.021))
=6.164

Invested Capital(Q: Oct. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=0.336 - 3.917 - ( 0.012 - max(0, 10.831 - 0.209+0.012))
=7.041

Note: The Operating Income data used here is four times the quarterly (Oct. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Cognetivity Neurosciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Oct. 2023 is calculated as:

ROC (Joel Greenblatt) %(Q: Oct. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jul. 2023  Q: Oct. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-1.952/( ( (0.036 + max(-8.347, 0)) + (0.032 + max(-9.689, 0)) )/ 2 )
=-1.952/( ( 0.036 + 0.032 )/ 2 )
=-1.952/0.034
=-5,741.18 %

where Working Capital is:

Working Capital(Q: Jul. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.183 + 0 + 0.034) - (3.45 + 0.087 + 5.027)
=-8.347

Working Capital(Q: Oct. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.174 + 0 + 0.023) - (3.917 + 0.075 + 5.894)
=-9.689

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Oct. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Cognetivity Neurosciences's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Oct. 2023 )
=-2.81/0.833
=-337.33 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cognetivity Neurosciences EBIT Related Terms

Cognetivity Neurosciences EBIT Historical Data

* Premium members only.

The historical data trend for Cognetivity Neurosciences's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cognetivity Neurosciences EBIT Chart

Cognetivity Neurosciences Annual Data
Trend Jan17 Jan18 Jan19 Jan20 Jan21 Jan22 Jan23
EBIT
Get a 7-Day Free Trial -2.78 -1.79 -1.20 -9.15 -4.43

Cognetivity Neurosciences Quarterly Data
Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.28 -1.14 -0.66 -0.52 -0.49

STU:1UB vs VEEV, GEHC, HQY: EBIT Comparison

For the Health Information Services subindustry, Cognetivity Neurosciences's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cognetivity Neurosciences EV-to-EBIT vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Cognetivity Neurosciences's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Cognetivity Neurosciences's EV-to-EBIT falls into.


Cognetivity Neurosciences EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Oct. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-2.81 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of €-2.81 Mil mean?
Cognetivity Neurosciences (STU:1UB) has a EBIT of €-2.81 Mil as of Oct. 2023. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Cognetivity Neurosciences.
Is Cognetivity Neurosciences' EBIT too high?
Cognetivity Neurosciences' current EBIT is €-2.81 Mil.
How does Cognetivity Neurosciences' EBIT compare to VEEV and GEHC?
Cognetivity Neurosciences' EBIT of €-2.81 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Healthcare Providers & Services company?
A good EBIT depends on the Healthcare Providers & Services industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Cognetivity Neurosciences. Cognetivity Neurosciences's current EBIT is €-2.81 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cognetivity Neurosciences stock overvalued right now?
Cognetivity Neurosciences (STU:1UB) has a current EBIT of €-2.81 Mil. The current EBIT is €-2.81 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Cognetivity Neurosciences (STU:1UB), the current EBIT is €-2.81 Mil as of Oct. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cognetivity Neurosciences Business Description

Address 800 West Pender Street, Suite 1430, Vancouver, BC, CAN, V6C 2V6
Cognetivity Neurosciences Ltd is a technology company developing a cognitive testing platform, the Integrated Cognitive Assessment (ICA), for use in medical, commercial, and consumer environments for potentially allowing early diagnosis of dementia. The Company is considered operating in one segment for development of the ICA platform. Its geographical areas include Canada, United Kingdom and Dubai.